临床Ⅱ期鼻咽癌的治疗进展  

Advances in Treatment of StageⅡNasopharyngeal Carcinoma

作　　者：易俊林[1] 高黎[1] 

机构地区：[1]中国医学科学院肿瘤医院放疗科,北京市100021

出　　处：《中国肿瘤临床》2012年第24期2047-2050,共4页Chinese Journal of Clinical Oncology

摘　　要：临床Ⅱ期鼻咽癌的治疗是鼻咽癌临床研究中的一个热点。常规放射治疗下,5年总生存率达74%～87%,远处转移为主要的失败原因,同期化疗可通过降低远处转移率而改善预后。常规放射治疗对正常组织损伤较大。调强放射治疗技术提高了局部控制和总生存率,同时对腮腺功能起到明显的保护作用。调强放射治疗联合同步化疗的疗效有待进一步研究。Stage II nasopharyngeal carcinoma （NPC） has been one of the hot issues in NPC clinical research over the past few years. The five-year overall survival reaches 74% to 87% after conventional two-dimensional radiotherapy, with distant metastasis as the main failure pattern. Concurrent chemo-radiotherapy improves the prognosis of stage II NPC in terms of decreasing distant metastasis. The acute and late complications more commonly occur during conventional radiotherapy. The local control, overall survival, and parotid function are improved by intensity-modulated radiotherapy. However, further studies on the participation of concurrent chemotherapy and intensity modulation radiated therapy in stage II NPC are warranted.

关 键 词：鼻咽恶性肿瘤 Ⅱ期 放射治疗 化学治疗 

分 类 号：R739.63[医药卫生—肿瘤]